期刊
JOURNAL OF SURGICAL ONCOLOGY
卷 114, 期 8, 页码 951-958出版社
WILEY-BLACKWELL
DOI: 10.1002/jso.24462
关键词
fluorescence-guided surgery; colon-cancer liver metastasis; orthotopic-liver metastasis model; fluorescent anti-CEA antibody; survival; disease-free survival
资金
- US National Cancer Institute [CA126023, CA142669]
- JSPS KAKENHI [26830081, 26462070, 24592009]
- NIH/NCI [T32CA121938]
- Grants-in-Aid for Scientific Research [26462070] Funding Source: KAKEN
Background and Objectives: Delineation of adequate tumor margins is critical in oncologic surgery, particularly in resection of metastatic lesions. Surgeons are limited in visualization with bright-light surgery, but fluorescence-guided surgery (FGS) has been efficacious in helping the surgeon achieve negative margins. Methods: The present study uses FGS in a mouse model that has undergone surgical orthotopic implantation (SOI) of colorectal liver metastasis tagged with green fluorescent protein (GFP). An anti-CEA antibody conjugated to DyLight 650 was used to highlight the tumor. Results: The fluorescent antibody clearly demarcated the lesion at deeper tissue depth compared to GFP. Fluorescence of the anti-CEA-DyLight650 showed maximal tumor-to-liver contrast at 72 hr. Fifteen mice underwent bright-light surgery (BLS) versus FGS with GFP versus FGS with anti-CEA-DyLight650. Mice that underwent FGS had a significantly smaller area of residual tumor (P < 0.001) and significantly longer overall survival (P < 0.001) and disease-free survival (P < 0.001). Within the two FGS groups, mice undergoing surgery with anti-CEA-DyLight650 improved survival compared to only GFP labeling. Conclusions: In the present report, we demonstrate that an anti-CEA antibody conjugated to a DyLight 650 nm dye clearly labeled colon cancer liver metastases, thereby enabling successful FGS. (C) 2016 Wiley Periodicals, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据